We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .
Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up
Abstract Extensively hydrolyzed ( EH ) formula with Lactobacillus rhamnosus GG ( LGG ) was demonstrated to alleviate cow ’s milk allergy ( CMA ) symptoms and promote faster acquisition of tolerance to cow ’s milk protein . We previously demonstrated that partially hydrolyzed ( PH ) and EH formulas with LGG supported normal growth in healthy-term infants through 120 days of age . The objective of the current study was to evaluate growth , development , and specific adverse events through 5 years of age in participants from that cohort who continued receiving study formula . Infants who completed a double-blind , r and omized growth and tolerance study were eligible to continue receiving the assigned study formula through 1 year of age ( control : EH casein formula , EHF , or one of two investigational formulas : EH casein formula with LGG ( EHF-LGG ) or a PH formula with LGG ( PHF-LGG ) ) and participate in follow-up through 5 years of age . Anthropometric measures , behavior development , and specific adverse events were recorded . No significant differences in achieved weight and height or behavioral development outcomes at 3 or 5 years of age were observed among study groups . Few statistically significant differences in the incidence of specific infection-related events through years 3 or 5 were observed among study groups , none of which were considered clinical ly relevant . Conclusion : Extensively and partially hydrolyzed formulas with LGG were associated with normal growth and development and long-term safety through 5 years of age . What is Known:• Infants with cow ’s milk allergy often experience allergic manifestations that can lead to poor nutrition status and poor growth.• Providing partially hydrolyzed ( PH ) and EH formulas with or without LGG in infants can support normal growth in healthy-term infants . What is New:• This study provides long-term safety data for the first 5 years of life on the use of extensively and partially hydrolyzed formulas with LGG when fed through 1 year of age.• Extensively and partially hydrolyzed formulas with LGG are associated with normal growth , development , and long-term safety through 5 years of age
We found no evidence to support short-term or prolonged feeding with a hydrolysed formula compared with exclusive breast feeding for prevention of allergic disease .
Very low- quality evidence indicates that short-term use of an EHF compared with a CMF may prevent infant CMA .
Further trials are recommended before implementation of this practice .We found no evidence to support prolonged feeding with a hydrolysed formula compared with a CMF for prevention of allergic disease in infants unable to be exclusively breast fed
BACKGROUND Infant formulas containing hydrolysed proteins have been widely advocated for preventing allergic disease in infants , in place of st and ard cow 's milk formula ( CMF ) .
However , it is unclear whether the clinical trial evidence supports this .
OBJECTIVES To compare effects on allergic disease when infants are fed a hydrolysed formula versus CMF or human breast milk .
If hydrolysed formulas are effective , to determine what type of hydrolysed formula is most effective , including extensively or partially hydrolysed formula ( EHF/PHF ) .
To determine whether infants at low or high risk of allergic disease , and whether infants receiving early short-term ( first few days after birth ) or prolonged formula feeding benefit from hydrolysed formulas .